A-Alpha Bio has developed a genetically engineered platform technology, called AlphaSeq, for measuring interactions between proteins that can be used to discover and optimize life-saving drugs. AlphaSeq was invented and developed by A-Alpha Bio's founders Drs. David Younger and Randolph Lopez, and Scientific Advisors, Drs. David Baker and Eric Klavins, at the University of Washington (UW). AlphaSeq enables the measurement of millions of interactions between proteins with high quantitative accuracy.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/27/19 | $2,800,000 | Seed |
AME Cloud Ventures Boom Capital Madrona Venture Group OS Fund  Sahsen Ventures Washington Research Foundation | undisclosed |
| 09/08/21 | $20,000,000 | Series A |
Lux Capital Madrona Venture Group Perceptive Advisors | undisclosed |
| 07/25/23 | $22,400,000 | Series A-2 |
Breakout Ventures Madrona Venture Group Perceptive Xontogeny Ventures | undisclosed |
